by In2Pharma | May 9, 2019 | News
The Netherlands The Medicines Evaluation Board (MEB) will no longer publish full product information about the active substance of generic medicines on its website if there is still a patent on one of the indications. A generic drug may not be sold for indications...
by In2Pharma | May 9, 2017 | News
MEB The Medicines Evaluation Board (MEB) introduced MEB 48, a new policy concerning the application of marketing authorizations for medicines that are identical to medicines already authorized. For this, a national informed consent marketing authorization application...
